



5 **Supplementary Figure 1**

6 **A)**



7
8 **B)**



9

10 **Supplementary Figure 1. A) CD11b, CD163 and TLR4 expression before and after DAAs**
 11 **treatment and in the HIV control group.** No differences were observed in the expression of
 12 these markers neither after DAAs nor compared with the HIV control group. CD163 expression
 13 in the intermediate subsets present higher levels in HIV control group respect the HIV/HCV

14 coinfecting group ($p=0.045$). The Wilcoxon test was used to compare HIV/HCV coinfecting
15 patients at baseline and end treatment. The Man-Whitney U was used to compare HIV/HCV-
16 coinfecting patients and HIV-monoinfecting patients control group. $*p<0.05$ and $**p<0.001$.
17 Abbreviation: NS, not significant; BL, HIV/HCV Baseline; ET, HIV/HCV End of treatment;
18 Ctrl, HIV control group. **B**) Schematic diagram of the gating strategy for monocyte subset in a
19 HIV/HCV coinfecting subject before and after DAAs treatment. Histogram representation of IL8
20 expression on classical, intermediate and nonclassical monocytes stimulated with LPS before
21 and after DAAs treatment as a representative example.

22


23 **Supplementary Table 1. Characteristics of the confirmatory cohort.**

Characteristic	HCV/HIV BL (n=18) <i>Confirmatory Cohort</i>	HCV/HIV BL (n=22)	P VALUE
Male sex, %	83	55	0.053
Age, y	51 [46-54]	47 [44-51]	0.186
CD4 Nadir counts, cells/ μ L	64 [19-121]	172 [50-393]	0.009
CD4 ⁺ T-cells counts, cells/ μ L	637 [325-781]	671 [446-957]	0.196
CD8 ⁺ T-cells counts, cells/ μ L	870 [575-1537]	1038 [607-1310]	0.701
Ratio CD4+ to CD8+ T Cells	0.69 [0.36-0.94]	0.72 [0.45-0.99]	0.540
HIV RNA (Log ₁₀ copies/mL)	1.3 [1.3-1.3]	1.3 [1.3 - 1.3]	1
HCV RNA (Log ₁₀ copies/mL)	6.4 [5.7 – 6.8]	6.8 [6.2 – 7.2]	0.020
HCV genotype-1, %	72.2	77.8	0.714
Fibrosis stage, %			
0-1	38.9	44.4	0.735
2	11.1	44.4	0.026
3	16.7	5.5	0.289
4	33.3	5.5	0.035
Cirrhosis, %	33.3	5.5	0.035

24 N.A.: Not applicable. Categorical variables were expressed as percentage and
 25 continuous variables as median, interquartile range [IQR]. Chi-square test and Mann-
 26 Whitney U test were used to compare categorical and continuous variables,
 27 respectively.

28
 29
 30

31 **Supplementary Figure 2.**




32
33

34 **Supplementary Figure 2. Results of the confirmatory cohort.** After treatment with DAAs the
 35 percentage of classical monocytes increased (p=0.02) and the intermediate and nonclassical
 36 subset diminished (p=0.005; p=0.03; respectively). In addition, a decrease in the levels of
 37 CCR5, CD49d and TLR4 expression after treatment with DAAs was observed in classical an
 38 intermediate monocytes (p=0.002; p=0.02; p=0.005; p=0.05; p=0.0004; p=0.01; respectively).
 39 No differences were observed in CD11b, CX3CR1, CD40 and TLR2 expression. . The
 40 Wilcoxon test was used to compare HIV/HCV coinfectd patients at baseline and at the end
 41 treatment. The Man-Whitney U was used to compare HIV/HCV-coinfectd patients and HIV-
 42 monoinfectd patients control group. *p<0.05 and **p<0.001. Abbreviation: NS, not
 43 significant; BL, HIV/HCV Baseline; ET, HIV/HCV End treatment; Ctrl, HIV control group.

44

45 **Supplementary Figure 3**



46
47

48 **Supplementary Figure 3. Effect of DAAs in the levels of IL6, TNF- α and hsCRP levels**
49 **changes after DAAs therapy.** The Wilcoxon test was used to compare HIV/HCV-coinfected
50 patients at baseline and end treatment. The Man-Whitney U was used to compare HIV/HCV-
51 coinfecting patients and HIV-monoinfected patients control group. Abbreviation: hsCRP, high
52 sensitivity C reactive protein; NS, not significant; BL, HIV/HCV Baseline; ET, HIV/HCV End
53 treatment; Ctrl, HIV control group.

54 **Supplementary Table 2. Multiple cytokine combinations in the different monocyte**
 55 **subsets after LPS estimation.**


IL1 α IL1 β IL6 IL8 IL10 TNF α ^a	Classical Monocytes		Intermediate Monocytes		Nonclassical Monocytes	
	BL vs ET ^b	ET vs Ctrl ^c	BL vs ET	ET vs Ctrl	BL vs ET	ET vs Ctrl
+++++	0.024	0.564	0.671	0.802	1.000	1.000
-++++	0.023	0.020	0.315	0.725	0.755	0.802
+ - + + +	0.229	0.451	0.932	0.802	1.000	1.000
++ - + + +	0.005	0.108	0.193	0.802	0.887	0.802
+++ - + +	0.734	0.328	0.051	0.841	0.470	1.000
++++ - +	0.054	0.269	0.552	0.802	1.000	1.000
++++ + -	0.671	0.280	0.810	1.000	1.000	1.000
-- + + + +	0.193	0.006	0.479	0.451	0.630	1.000
- + - + + +	0.016	0.004	0.030	1.000	0.755	0.802
+ - - + + +	0.044	0.132	0.630	1.000	0.865	0.880
- + + - + +	0.218	0.012	0.218	0.422	0.315	0.980
+ - + - + +	0.229	1.000	0.887	0.802	0.630	1.000
+ + - - + +	0.095	0.063	0.041	0.651	0.315	0.132
- + + + - +	0.066	0.016	0.506	0.280	1.000	1.000
+ - + + - +	0.119	0.315	0.810	1.000	0.810	1.000
++ - + - +	0.004	0.688	0.229	1.000	0.810	1.000
+++ - - +	0.955	0.482	0.470	1.000	0.630	1.000
- + + + + -	0.497	0.001	0.229	1.000	1.000	1.000
+ - + + + -	0.350	0.802	0.810	1.000	0.755	0.802
++ - + + -	0.282	0.160	0.630	1.000	1.000	1.000
+++ - + -	0.734	0.315	1.000	1.000	1.000	1.000
++++ + - -	0.188	0.380	0.470	1.000	1.000	1.000
- - - + + +	0.002	0.001	0.174	0.616	0.336	1.000
- - + - + +	0.745	0.002	0.821	0.292	0.955	0.315
- + - - + +	0.257	0.000	0.149	0.292	0.799	0.145
+ - - - + +	0.034	0.014	0.084	0.616	0.039	0.292
- - + + - +	0.100	0.007	0.372	0.315	0.723	0.616
- + - + - +	0.022	0.025	0.051	0.900	0.810	1.000
+ - - + - +	0.000	0.530	0.149	0.670	0.713	0.880
- + + - - +	0.350	0.209	0.013	0.725	0.552	0.802
+ - + - - +	0.257	0.841	0.470	1.000	0.810	1.000
+ + - - - +	0.015	0.436	0.229	1.000	0.174	0.802
- - + + + -	0.843	0.002	0.202	0.802	1.000	1.000
- + - + + -	0.084	0.000	0.084	0.802	1.000	1.000
+ - - + + -	0.017	0.315	0.149	1.000	0.810	1.000
- + + - + -	0.444	0.009	0.269	0.763	0.766	0.880
+ - + - + -	0.017	0.451	0.692	0.802	1.000	1.000
+ + - - + -	0.977	0.050	0.092	1.000	0.630	1.000

- + + + - -	0.506	0.002	0.039	0.564	0.932	0.802
+ - + + - -	0.021	0.422	0.462	0.616	1.000	1.000
+ + - + - -	0.041	0.192	0.336	1.000	1.000	1.000
+ + + - - -	0.497	0.802	0.810	0.670	1.000	1.000
- - - - + +	0.444	0.000	0.745	0.002	0.179	0.008
- - - + - +	0.002	0.005	0.003	0.960	0.213	0.547
- - + - - +	0.552	0.018	0.777	0.688	0.110	0.616
- + - - - +	0.060	0.393	0.029	0.547	0.229	0.530
+ - - - - +	0.004	0.633	0.149	0.564	0.002	0.407
- - - + + -	0.054	0.003	0.030	0.219	0.692	0.960
- - + - + -	0.671	0.001	0.223	0.145	0.133	0.145
- + - - + -	0.234	0.001	0.005	0.960	0.411	0.616
+ - - - + -	0.016	0.120	0.008	1.000	0.470	1.000
- - + + - -	0.590	0.003	0.403	0.006	0.515	0.315
- + - + - -	0.257	0.012	0.329	0.366	0.396	0.802
+ - - + - -	0.000	0.228	0.004	1.000	0.157	0.802
- + + - - -	0.799	0.011	0.079	0.514	0.350	0.451
+ - + - - -	0.218	0.025	0.282	0.393	0.087	0.616
+ + - - - -	0.004	0.763	0.229	0.393	0.810	1.000
- - - - - +	0.070	0.016	0.022	0.063	0.295	0.160
- - - - + -	0.524	0.132	0.041	0.120	0.506	0.422
- - - + - -	0.028	0.145	0.098	0.063	0.006	0.547
- - + - - -	0.865	0.002	0.899	0.035	0.571	0.025
- + - - - -	0.357	0.467	0.000	0.192	0.034	0.841
+ - - - - -	0.002	0.228	0.003	0.744	0.008	0.802

56

57 ^aMonocyte subset showing the presence (+, symbol) or absence (-, symbol) of cytokine
58 combinations in the order represented in the column heading. ^bp value of Wilcoxon test
59 was used to compared variables before (BL) and after treatment (ET). ^cp value of Chi-
60 square test and Mann-Whitney U test were used to compare categorical and continuous
61 variables respectively, between ET and HIV monoinfected control group. Significant
62 values are shadowed.

63 **Supplementary Figure 4.**



64
65

66 **Supplementary Figure 4. Association of cell-associated HIV-1 DNA levels with activation**
67 **of monocytes at the end of treatment.** Graphical representation of the relationship between
68 HIV-1 DNA Log₁₀ copies/10⁶ PBMCs and the percentage of monocytes expressing CD40,
69 CCR5 and CD11b after DAAs treatment. Spearman correlation coefficient test was used.

70